... Journal of Diabetes Anti-VEGF Treatment of Diabetic Macular Edema: Two-Year Visual Outcomes in Routine Clinical Practice — Journal of Ophthalmology Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy — Life FDA Approves Genentech’s Susvimo ...
4 Diabetic Macular Edema Treatments: Injections, Surgery, and More
... Journal of Diabetes Anti-VEGF Treatment of Diabetic Macular Edema: Two-Year Visual Outcomes in Routine Clinical Practice — Journal of Ophthalmology Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy — Life FDA Approves Genentech’s Susvimo ...
... injections for diabetic retinopathy include: Aflibercept (Eylea) Bevacizumab (Avastin), used off-label (outside of approved use for cancer) Brolucizumab-dbll (Beovu), approved for diabetic macular edema but not diabetic retinopathy Faricimab-svoa (Vabysmo), approved for diabetic macular edema but not diabetic retinopathy Ranibizumab (Lucentis injection; Susvimo ...
Can Diabetic Retinopathy Be Reversed? Injections, Diet, and More
... injections for diabetic retinopathy include: Aflibercept (Eylea) Bevacizumab (Avastin), used off-label (outside of approved use for cancer) Brolucizumab-dbll (Beovu), approved for diabetic macular edema but not diabetic retinopathy Faricimab-svoa (Vabysmo), approved for diabetic macular edema but not diabetic retinopathy Ranibizumab (Lucentis injection; Susvimo ...
... Most doctors usually first choose a type of anti-VEGF therapy, such as: Aflibercept (Eylea) Bevacizumab (Avastin) Faricimab-svoa (Vabysmo) Ranibizumab — Sold as Lucentis (injection) or Susvimo (a port delivery system) Steroids are another type of medication that can be delivered by intravitreal injection. ...